Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amplitude Inc (AMPL) vs Merck & Co., Inc. (MRK) Price & Performance

Amplitude IncTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Amplitude Inc vs Merck & Co., Inc. — how do they compare? Amplitude Inc trades at $12.78 (market cap $1.59B), while Merck & Co., Inc. trades at $130.3 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 202.4× Amplitude Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Amplitude Inc pays none. Which is the better fit depends on your goals.

AMPLMRK
Market Cap
$1.59B$321.77B
Sector
TechnologyHealth
52-Week High
$12.69$131.84
52-Week Low
$5.61$77.60
Enterprise Value
$1.45B$368.53B
Dividend Yield
2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amplitude Inc

No Aura AI signal available yet.

Merck & Co., Inc.

Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.

The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amplitude Inc

Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.

Read more on AMPL

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK